GlassScriptPhysician profile
Tejwant Singh
NPI 1841433638
$3,001.63
in general payments reported to CMS, 2019-2025
23 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $71.61 · 2021: $519 · 2022: $698 · 2023: $296 · 2024: $359 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $999.98 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $259.07 | 2019-2025 | |
| Abbott Laboratories | $178.02 | 2021-2024 | Xience Skypoint |
| Medtronic Vascular, INC. | $157.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $154.35 | 2019-2022 | |
| Medtronic, INC. | $143.91 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Boston Scientific Corporation | $141.28 | 2022 | |
| Amgen INC. | $127.08 | 2019 | |
| Abiomed | $124.98 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.24 | 2023-2025 | Lifevest |
| Gilead Sciences, INC. | $110.15 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $90.15 | 2023 | Camzyos |
| Pfizer INC. | $82.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.58 | 2019 | |
| Heartflow, INC. | $49.98 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $38.58 | 2023 | Assure Wcd |
| Cardiva Medical, INC. | $36.92 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Biotronik INC. | $34.66 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $27.48 | 2024 | |
| Novo Nordisk INC | $25.15 | 2024 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $19.19 | 2023 | Opsumit, Uptravi |
| Kowa Pharmaceuticals America, INC. | $12.32 | 2019 | |
| Cvrx, INC. | $5.54 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejwant Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.